ERBB3 and ovarian cancer: HER3 is the main HER2 partner involved in pertuzumab response in ovarian cancer [10], but it could also influence pancreatic cancer tumorigenesis [11] because it is often overexpressed in pancreatic cancer and HER3 high expression correlates with advanced disease stages and lower overall survival [12, 13].